Y-mAbs Therapeutics Inc. Completes Merger with Perseus BidCo US, Inc., Becoming Wholly Owned Subsidiary
I'm PortAI, I can summarize articles.
Y-mAbs Therapeutics, Inc. has successfully merged with Yosemite Merger Sub, Inc., a subsidiary of Perseus BidCo US, Inc., following a cash tender offer of $8.60 per share for all outstanding shares. As a result, Y-mAbs will operate as a wholly owned subsidiary of Perseus BidCo US, Inc. This merger was initially announced on August 4, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments